Evolution of the Average Target: Virbac SA

Evolution of the Target Price: Virbac SA

Changes in Analyst Recommendations: Virbac SA

3841c94b6.yGBqwO4_HN8LdoMFslmyhPV5k-LzgOabARd-lFKU-7s.gVUT8dkJVLdqPMhq-gbjs5NL6duj56vdY3lOxDXijdG7VDyJ13IrjD9H7A~fa186654ee1555703a26c2d2af1ce819
07-21 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
07-14 Where would AI lead Pharma in the long run? Alphavalue
05-11 Virbac continues decline despite positive recommendation Zonebourse
04-17 Virbac: 2026 starts on strong footing Alphavalue
03-19 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
03-18 Virbac in the green following results and outlook Zonebourse
01-20 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
01-20 Stifel Raises Price Target on Virbac Zonebourse
01-20 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
25-10-17 Virbac: Q3 crushed doubts about execution ability Alphavalue
25-09-17 The day the Fed resumed its rate cuts Zonebourse
25-09-15 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
25-07-17 Virbac: A healthy Q2 impresses the markets Alphavalue
25-07-03 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
25-07-03 Virbac: Oddo BHF upgrades stock Zonebourse
25-04-17 Virbac: brokers' advice following quarterly results Zonebourse
25-04-16 Virbac: Stifel remains bullish after quarterly results Zonebourse
25-04-16 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
25-04-16 Virbac: Stifel still buying after Q1 results Zonebourse
25-03-17 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
25-03-17 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
25-03-17 Virbac: Stifel raises its recommendation Zonebourse
25-01-17 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
25-01-17 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT
24-11-04 Virbac: Stifel lowers its target price for the stock Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+36.48%
+32.04%
+100.35%
+24.81%
+7.05%
+4.29%
- +29.87%
+8.33%
- +32.16%
Average +30.60%
Weighted average by Cap. +36.25%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
330.50EUR
Average target price
411.88EUR
Spread / Average Target
+24.62%
High Price Target
440.00EUR
Spread / Highest target
+33.13%
Low Price Target
360.00EUR
Spread / Lowest Target
+8.93%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue Abhishek Raval
ODDO BHF
TP ICAP Midcap
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
330.50EUR
Average target price
411.88EUR
Spread / Average Target
+24.62%

Quarterly revenue - Rate of surprise